• Prostate and other male cancers

Jevtana Generic Name & Formulations

General Description

Cabazitaxel 60mg/1.5mL; soln for IV infusion after dilution; contains polysorbate 80, diluent contains ethanol.

Pharmacological Class

Antimicrotubule agent.

How Supplied

Kit (single-use vial + diluent)—1


Generic Availability


Jevtana Indications


In combination with prednisone for the treatment of metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

Jevtana Dosage and Administration


Prophylax with G-CSF in those with high-risk clinical features; also should consider in all patients receiving a 25mg/m2 dose. Premedicate with IV antihistamine, corticosteroid, and H2 blocker 30mins before each dose (see full labeling) and with antiemetic (IV or oral as needed). Infuse over 1hr. 20mg/m2 every 3 weeks, with oral prednisone 10mg/day during treatment; 25mg/m2 may be used in select patients. Prolonged grade ≥3 neutropenia (>1 week), febrile neutropenia, grade ≥3 diarrhea, grade 2 peripheral neuropathy: delay treatment and/or reduce by one dose level (see full labeling). Discontinue if grade ≥3 peripheral neuropathy. Hepatic impairment: (mild): 20mg/m2; (moderate): 15mg/m2. If concomitant strong CYP3A inhibitor necessary, consider a 25% cabazitaxel dose reduction.


Not established.

Jevtana Contraindications


Neutrophil count ≤1,500cells/mm3. Allergy to polysorbate 80. Severe hepatic impairment (total bilirubin >3×ULN).

Jevtana Boxed Warnings

Boxed Warning

Neutropenia. Hypersensitivity.

Jevtana Warnings/Precautions


Risk of bone marrow suppression. High-risk clinical features (eg, older patients, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities); see Adults. Monitor CBCs weekly in 1st cycle and before each subsequent cycle. Patients with hemoglobin <10g/dL; monitor closely. Monitor for hypersensitivity reactions esp. during 1st and 2nd infusions; discontinue if occur. Increased risk of GI disorders in patients with neutropenia, age, or history of pelvic radiotherapy, adhesions, ulceration, and GI bleeding. Evaluate and treat if serious GI toxicity occurs; treatment delay or discontinuation may be needed. Underlying lung disease. Monitor closely for respiratory disorders; interrupt if new or worsening pulmonary symptoms develop. Monitor for cystitis in patients who previously received pelvic radiation; interrupt or discontinue if severe hemorrhagic cystitis occurs. Hepatic impairment (monitor). ESRD (CrCl <15mL/min). Elderly (increased toxicities); monitor closely. Embryo-fetal toxicity. Advise males with female partners of reproductive potential to use effective contraception during and for 3 months after the last dose. Pregnancy, nursing mothers: not established.

Jevtana Pharmacokinetics

See Literature

Jevtana Interactions


Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole); avoid. May be antagonized by rifampin. Increased GI toxicity with concomitant steroids, NSAIDs, antiplatelets, anticoagulants.

Jevtana Adverse Reactions

Adverse Reactions

Neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea (may be fatal), fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, alopecia; febrile neutropenia, renal failure, hypersensitivity reactions.

Jevtana Clinical Trials

See Literature

Jevtana Note

Not Applicable

Jevtana Patient Counseling

See Literature